Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Februar 2020 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics to Present at the BIO CEO & Investor Conference

TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
08. Januar 2020 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene...
21. November 2019 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma...
14. November 2019 07:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Announces Third Quarter 2019 Financial Results

TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update....
06. November 2019 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. ...
31. Oktober 2019 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
13. August 2019 07:15 ET | Quelle: VBL Therapeutics

VBL Therapeutics Announces Second Quarter 2019 Financial Results

TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update. ...
05. August 2019 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13

TEL AVIV, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
22. Juli 2019 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit

TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
04. Juni 2019 07:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today

TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International...

Vorherige Seite